Расчет внутренних течений жидкости в каналах с помощью пакета CFX

The paper describes approach for computation of fluid flows implemented in the software package CFX. The results of computation of a number of simple internal fluid flows in channels are presented and comparison with known experimental data is performed. Good correspondence of results was obtained both concerning the flow pattern and related integral values. When you are citing the document, use the following link http://essuir.sumdu.edu.ua/handle/123456789/48

Створення бібліотеки електронних підручників для студентів спеціальностей напряму "Інженерна механіка"

The article shows expediency of creation of a library of electronic manuals for students that represents a collection of learning courses written on CD. The authors describe their experience in creation of such a library. When you are citing the document, use the following link http://essuir.sumdu.edu.ua/handle/123456789/58

О двух способах анализа напряженного состояния вращающегося диска с разрезами

В данной работе рассмотрено решение задачи о напряжениях во вращающемся диске с разрезами двумя различными способами: для кругового диска с разрезами представления решений постоены с использованием функции Грина; для диска более сложной конфигурации - краевые условия на внешнем контуре сводятся к интегральному уравнению. Отмечается эффективность метода интегральных уравнений. При цитировании документа, используйте ссылку http://essuir.sumdu.edu.ua/handle/123456789/2971

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

BACKGROUND Patients with elevated triglyceride levels are at increased risk for ischemic events. Icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers triglyceride levels, but data are needed to determine its effects on ischemic events. METHODS We performed a multicenter, randomized, double-blind, placebo-controlled trial involving patients with established cardiovascular disease or with diabetes and other risk factors, who had been receiving statin therapy and who had a fasting triglyceride level of 135 to 499 mg per deciliter (1.52 to 5.63 mmol per liter) and a low-density lipoprotein cholesterol level of 41 to 100 mg per deciliter (1.06 to 2.59 mmol per liter). The patients were randomly assigned to receive 2 g of icosapent ethyl twice daily (total daily dose, 4 g) or placebo. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina. The key secondary end point was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. RESULTS A total of 8179 patients were enrolled (70.7% for secondary prevention of cardiovascular events) and were followed for a median of 4.9 years. A primary end-point event occurred in 17.2% of the patients in the icosapent ethyl group, as compared with 22.0% of the patients in the placebo group (hazard ratio, 0.75; 95% confidence interval [CI], 0.68 to 0.83; P<0.001); the corresponding rates of the key secondary end point were 11.2% and 14.8% (hazard ratio, 0.74; 95% CI, 0.65 to 0.83; P<0.001). The rates of additional ischemic end points, as assessed according to a prespecified hierarchical schema, were significantly lower in the icosapent ethyl group than in the placebo group, including the rate of cardiovascular death (4.3% vs. 5.2%; hazard ratio, 0.80; 95% CI, 0.66 to 0.98; P=0.03). A larger percentage of patients in the icosapent ethyl group than in the placebo group were hospitalized for atrial fibrillation or flutter (3.1% vs. 2.1%, P=0.004). Serious bleeding events occurred in 2.7% of the patients in the icosapent ethyl group and in 2.1% in the placebo group (P=0.06). CONCLUSIONS Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosapent ethyl twice daily than among those who received placebo. (Funded by Amarin Pharma; REDUCE-IT ClinicalTrials.gov number, NCT01492361